Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis
Maria Pia Sormani, Nicola De Rossi, Irene Schiavetti, et al.
Annals of Neurology (2021) Vol. 89, Iss. 4, pp. 780-789
Open Access | Times Cited: 432

Showing 1-25 of 432 citing articles:

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis, Mihir Kakara, Mark M. Painter, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 1990-2001
Open Access | Times Cited: 472
Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis
Amber Salter, Robert J. Fox, Scott D. Newsome, et al.
JAMA Neurology (2021) Vol. 78, Iss. 6, pp. 699-699
Open Access | Times Cited: 264
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Jeffrey A. Sparks, Zachary S. Wallace, Andrea M. Seet, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 9, pp. 1137-1146
Open Access | Times Cited: 212
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis
Steve Simpson, Edward De Brouwer, Tomáš Kalinčík, et al.
Neurology (2021) Vol. 97, Iss. 19
Open Access | Times Cited: 148
Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
Carla Tortorella, Alessandra Aiello, Claudio Gasperini, et al.
Neurology (2021) Vol. 98, Iss. 5
Open Access | Times Cited: 145
COVID-19 mRNA vaccination leading to CNS inflammation: a case series
Mahsa Khayat-Khoei, Shamik Bhattacharyya, Joshua Katz, et al.
Journal of Neurology (2021) Vol. 269, Iss. 3, pp. 1093-1106
Open Access | Times Cited: 116
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies
Anthony T. Reder, Diego Centonze, Maria L. Naylor, et al.
CNS Drugs (2021) Vol. 35, Iss. 3, pp. 317-330
Open Access | Times Cited: 112
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study
Natacha Madelon, Kim Lauper, Gautier Bréville, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e1037-e1045
Open Access | Times Cited: 107
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
Maria Pia Sormani, Marco Salvetti, Pierre Labauge, et al.
Annals of Clinical and Translational Neurology (2021) Vol. 8, Iss. 8, pp. 1738-1744
Open Access | Times Cited: 103
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
Sachin P. Gadani, Maria Reyes‐Mantilla, Larissa Jank, et al.
EBioMedicine (2021) Vol. 73, pp. 103636-103636
Open Access | Times Cited: 102
Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform
Brian MacKenna, Nicholas A. Kennedy, Amir Mehrkar, et al.
The Lancet Rheumatology (2022) Vol. 4, Iss. 7, pp. e490-e506
Open Access | Times Cited: 92
Therapeutic Advances in Multiple Sclerosis
Jennifer H. Yang, Torge Rempe, Natalie Whitmire, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 85
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function
Joseph J. Sabatino, Kristen Mittl, William Rowles, et al.
JCI Insight (2022) Vol. 7, Iss. 4
Open Access | Times Cited: 75
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
de Sèze, Élisabeth Maillart, Antoine Guéguen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 62
Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections
Annette Langer‐Gould, Bonnie H. Li, Jessica Smith, et al.
Neurology Neuroimmunology & Neuroinflammation (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 16
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 8, Iss. 5
Open Access | Times Cited: 86
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
Monica Margoni, Paolo Preziosa, Massimo Filippi, et al.
Journal of Neurology (2021) Vol. 269, Iss. 3, pp. 1316-1334
Open Access | Times Cited: 82
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
Céline Louapre, Michella Ibrahim, Élisabeth Maillart, et al.
Journal of Neurology Neurosurgery & Psychiatry (2021) Vol. 93, Iss. 1, pp. 24-31
Open Access | Times Cited: 80
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review
Maryam Sharifian, Mohammad Ali Sahraian, Giulia Fadda, et al.
Multiple Sclerosis and Related Disorders (2021) Vol. 50, pp. 102800-102800
Open Access | Times Cited: 73
COVID-19 Outcomes in Patients Undergoing B Cell Depletion Therapy and Those with Humoral Immunodeficiency States: A Scoping Review
Jessica Jones, Aiman Faruqi, James Sullivan, et al.
Pathogens and Immunity (2021) Vol. 6, Iss. 1, pp. 76-103
Open Access | Times Cited: 71
COVID-19 Severity in Multiple Sclerosis
Maria Pia Sormani, Irene Schiavetti, Luca Carmisciano, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 69
First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine
Joachim Havla, Yannick Schultz, Hanna Zimmermann, et al.
Journal of Neurology (2021) Vol. 269, Iss. 1, pp. 55-58
Open Access | Times Cited: 68
Incidence, Clinical Presentation, Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies
Jorge Calderón‐Parra, Elena Múñez, Ana Fernández‐Cruz, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 10, pp. 1786-1794
Open Access | Times Cited: 63
Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel
Itay Lotan, Adi Wilf‐Yarkoni, Yitzhak Friedman, et al.
European Journal of Neurology (2021) Vol. 28, Iss. 11, pp. 3742-3748
Open Access | Times Cited: 58
Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis
Xi Wu, Lu Wang, Lu Shen, et al.
EBioMedicine (2022) Vol. 81, pp. 104102-104102
Open Access | Times Cited: 51
Page 1 - Next Page

Scroll to top